

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Ann M. Lees et al.                      Art Unit :  
Serial No. : Unassigned                              Examiner :  
Filed : Herewith  
Title : NOVEL LOW DENSITY LIPOPROTEIN BINDING PROTEINS AND THEIR  
USE IN DIAGNOSING AND TREATING ATHEROSCLEROSIS

Commissioner for Patents  
Washington, D.C. 20231

PRELIMINARY AMENDMENT

Prior to examination, please amend the application as follows.

In the Specification:

Replace the paragraph beginning at page 1, line 5, with the following rewritten paragraph:

--This application is a divisional of U.S. Patent Application No. 09/616,289, filed July 14, 2000, which is a continuation-in-part of U.S. Patent Application No. 09/517,849, filed March 2, 2000, which is a continuation-in part of U.S. Patent Application No. 08/979,608, filed November 26, 1997, which claimed priority from U.S. Provisional Application No. 60/031,930, filed November 27, 1996, and U.S. Provisional Application No. 60/048,547, filed June 3, 1997. These applications are incorporated herein by reference in their entirety.--

Replace the paragraph beginning at page 6, line 7, with the following rewritten paragraph:

--Fig. 3 depicts the amino acid sequence of amino acids 319 to 550 of rabbit LBP-2 (SEQ ID NO: 3).--

CERTIFICATE OF MAILING BY EXPRESS MAIL

Express Mail Label No. EL 932079148 US

I hereby certify under 37 CFR §1.10 that this correspondence is being deposited with the United States Postal Service as Express Mail Post Office to Addressee with sufficient postage on the date indicated below and is addressed to the Commissioner for Patents, Washington, D C. 20231.

Date of Deposit 12-17-01

Signature Henry Jenkins

Typed or Printed Name of Person Signing Certificate Henry Jenkins

Replace the paragraph beginning at page 6, line 9, with the following rewritten paragraph:

--Fig. 4 depicts the amino acid sequence of amino acids 299 to 550 of rabbit LBP-2 (SEQ ID No: 4).--

Replace the paragraph beginning at page 6, line 28, with the following rewritten paragraph:

--Fig. 10 depicts the cDNA sequence encoding rabbit LBP-1 (SEQ ID NO: 10) and the corresponding amino acid sequence (SEQ ID NO:1). Differences in amino acids between rabbit and human LBP-1 are depicted in bold type.--

Replace the paragraph beginning at page 6, line 31, with the following rewritten paragraph:

--Fig. 11 depicts a cDNA sequence encoding a portion of rabbit LBP-2 (SEQ ID NO: 11) and the corresponding amino acid sequence (SEQ ID NO:2). Differences in amino acids between rabbit and human LBP-2 are depicted in bold type. Where the sequences depicted in Fig. 2A and Fig. 11 differ, Fig. 2A represents the rabbit LBP-2 sequence.--

Replace the paragraph beginning at page 7, line 4, with the following rewritten paragraph:

--Fig. 12 depicts a cDNA sequence of nucleotides 256 to 1617 (SEQ ID NO: 12) of SEQ ID NO: 11 of rabbit LBP-2 and the corresponding amino acid sequence (SEQ ID NO:3).--

Replace the paragraph beginning at page 7, line 6, with the following rewritten paragraph:

--Fig. 13 depicts a cDNA sequence of nucleotides 196 to 1617 (SEQ ID NO: 13) of SEQ ID NO: 11 of rabbit LBP-2 and the corresponding amino acid sequence (SEQ ID NO:4).--

Replace the paragraph beginning at page 7, line 8, with the following rewritten paragraph:

--Fig. 14 depicts the cDNA sequence encoding rabbit LBP-3 (SEQ ID NO: 14) and the corresponding amino acid sequence (SEQ ID NO:5). Differences in amino acids between rabbit and human LBP-3 are depicted in bold type.--

Replace the paragraph beginning at page 7, line 11, with the following rewritten paragraph:

--Fig. 15 depicts the cDNA sequence encoding human LBP-1 (SEQ ID NO: 15) and the corresponding amino acid sequence (SEQ ID NO:6). Differences in amino acids between rabbit and human LBP-1 are depicted in bold type.--

Replace the paragraph beginning at page 7, line 14, with the following rewritten paragraph:

--Fig. 16 depicts a cDNA sequence encoding a portion of human LBP-2 (SEQ ID NO: 16) and the corresponding amino acid sequence (SEQ ID NO:7). Differences in amino acids between rabbit and human LBP-2 are depicted in bold type.--

Replace the paragraph beginning at page 7, line 17, with the following rewritten paragraph:

--Fig. 17 depicts a cDNA sequence encoding a portion of human LBP-3 (SEQ ID NO: 17) and the corresponding amino acid sequence (SEQ ID NO:8). Differences in amino acids between rabbit and human LBP-3 are depicted in bold type. Where the sequences depicted in Fig. 8A and Fig. 17 differ, Fig. 8A represents the human LBP-3 sequence.--

Replace the paragraph beginning at page 7, line 21, with the following rewritten paragraph:

--Fig. 18 depicts the cDNA sequence encoding BHF-1 (SEQ ID NO: 18) and corresponding amino acid sequence (SEQ IDNO:9).--

10/2/2017 10:23:00 AM

Replace the paragraph beginning at page 7, line 22, with the following rewritten paragraph:

--Fig. 19 corresponds to the amino acid sequence of rabbit LBP-1 (top sequence; SEQ ID NO:1) in alignment with the amino acid sequence of human LBP-1 (bottom sequence; SEQ ID NO:6).--

Replace the paragraph beginning at page 7, line 24, with the following rewritten paragraph:

--Fig. 20 corresponds to the amino acid sequence of a portion of the amino acid sequence of rabbit LBP-2 (top sequence; amino acid residues 331-550 of SEQ ID NO:47) in alignment with a portion of the amino acid sequence of human LBP-2 (bottom sequence; SEQ ID NO:7).--

Replace the paragraph beginning at page 7, line 27, with the following rewritten paragraph:

--Fig. 21 corresponds to the amino acid sequence of rabbit LBP-3 (top sequence; SEQ ID NO:5) in alignment with the amino acid sequence of a portion of human LBP-3 (bottom sequence; SEQ ID NO:44).--

Replace the paragraph beginning at page 7, line 30, with the following rewritten paragraph:

--Fig. 22 depicts the genomic sequence of human LBP-1 (SEQ ID NO:49) and corresponding amino acid sequence (SEQ ID NO:6).--

Replace the paragraph beginning at page 7, line 31, with the following rewritten paragraph:

--Fig. 23 depicts the genomic sequence of human LBP-2 (SEQ ID NO:50) and corresponding amino acid sequence (SEQ ID NO:43).--

Replace the paragraph beginning at page 8, line 1, with the following rewritten paragraph:

--Fig. 24 depicts the genomic sequence of human LBP-3 (SEQ ID NO:51) and corresponding amino acid sequence (SEQ ID NO:44).--

Replace the paragraph beginning at page 8, line 11, with the following rewritten paragraph:

--This invention provides for an isolated polynucleotide comprising a polynucleotide encoding the polypeptide having the amino acid sequence of rabbit LBP-1 as set forth in Fig. 1 (SEQ ID NO: 1); rabbit LBP-2 as set forth in Fig. 2A (SEQ ID NO: 47); a portion of rabbit LBP-2 as set forth in Fig. 2B (SEQ ID NO: 2); 319 to 550 of rabbit LBP-2 as set forth in Fig. 3 (SEQ ID NO: 3); 299 to 550 of rabbit LBP-2 as set forth in Fig. 4 (SEQ ID NO: 4); rabbit LBP-3 as set forth in Fig. 5 (SEQ ID NO: 5); human LBP-1 as set forth in Fig. 6 (SEQ ID NO: 6); human LBP-2 as set forth in Fig. 7A (SEQ ID NO: 43); 322 to 538 of human LBP-2 as set forth in Fig. 7B (SEQ ID NO: 7); human LBP-3 as set forth in Fig. 8A (SEQ ID NO: 44); 17-546 of human LBP-3 as set forth in Fig. 8B (SEQ ID NO: 8); 14 to 33 of human (SEQ ID NO:6) or rabbit (SEQ ID NO:1) LBP-1, called BHF-1, as set forth in Fig. 9 (SEQ ID NO: 9); a polynucleotide capable of hybridizing to and which is at least about 80% identical, more preferably at least about 90% identical, more preferably yet at least about 95% identical, and most preferably at least about 98% identical to any of the above polynucleotides, and wherein the encoded polypeptide is capable of binding to LDL; or a biologically active fragment of any of the above polynucleotides wherein the encoded polypeptide is capable of binding to LDL.--

Replace the paragraph beginning at page 11, line 26, with the following rewritten paragraph:

--This invention also includes an isolated polypeptide comprising a polypeptide having amino acid residues 329-343 (SEQ ID NO: 19), 329-354 (SEQ ID NO: 20), 344-354 (SEQ ID NO: 21) or 529-538 (SEQ ID NO: 22) as set forth in Fig. 7A (SEQ ID NO: 47); amino acid residues 14-43 (SEQ ID NO: 23) or 38-43 (SEQ ID NO: 24) as set forth in Fig. 1 (SEQ ID NO: 1) and Fig. 6 (SEQ ID NO: 6); amino acid residues 338-353 (SEQ ID NO: 25), 338-365 (SEQ ID

NO: 26), 354-365 (SEQ ID NO: 27) or 444-453 (SEQ ID NO: 28) as set forth in Fig. 2A (SEQ ID NO: 47); amino acid residues 96-110 (SEQ ID NO: 29) as set forth in Fig. 5 (SEQ ID NO: 5); and amino acid residues 69-75 (SEQ ID NO: 41) as set forth in Fig. 8A (SEQ ID NO:44); or a polypeptide which is at least about 80% identical, more preferably at least about 90% identical, more preferably yet at least about 95% identical, and most preferably at least about 98% identical to the above polypeptides, and wherein said polypeptide is capable of binding to LDL; or a biologically active fragment of any of the above polypeptides wherein the fragment is capable of binding to LDL.--

Replace the paragraph beginning at page 34, line 3, with the following rewritten paragraph:

--Thus, a diagnostic embodiment of the invention is the adaptation of, e.g., a peptide complementary to one of the LBPs, by radiolabeling it and using it as an injectable imaging agent for detection of occult atherosclerosis. The peptide is selected from those known to bind to LBPs, e.g., RRRRRRRR (SEQ ID NO:52) or KKLKLXX (SEQ ID NO:53), or any other polycationic peptide which binds to the highly electronegative domains of the LBPs. For extracorporeal detection with a gamma scintillation (Anger) camera, technetium-binding ligands, e.g., CGC, GGCGC, or GGCGCF, can be incorporated into the peptides at the N-terminus or C-terminus for <sup>99m</sup>Tc labeling. For external imaging by magnetic resonance imaging (MRI), e.g., the gadolinium-binding chelator, diethylene triamine penta-acetic acid (DTPA), is covalently bound to the N- or C-terminus of the peptides. In yet other embodiments, the LBP-binding peptides are covalently bound, e.g., to magnetic ion oxide particles by standard methods known to those skilled in the art, e.g., conjugating the peptides with activated polystyrene resin beads containing magnetic ion oxide.--

In the Claims:

Cancel claims 1-37 without prejudice.

Add new claims 38-95.

--38. An isolated nucleic acid comprising a nucleotide sequence that encodes a polypeptide comprising an amino acid sequence that is at least about 80% identical to the sequence of SEQ ID NO:5, wherein the polypeptide binds to LDL.

39. The nucleic acid of claim 38, wherein the amino acid sequence is at least about 90% identical to the sequence of SEQ ID NO:5.

40. The nucleic acid of claim 38, wherein the amino acid sequence is at least about 95% identical to the sequence of SEQ ID NO:5.

41. An isolated nucleic acid comprising a nucleotide sequence that encodes a polypeptide comprising the sequence of SEQ ID NO:5.

42. The nucleic acid of claim 41, wherein the polypeptide consists of the sequence of SEQ ID NO:5.

43. An isolated nucleic acid comprising a nucleotide sequence that encodes a polypeptide comprising an amino acid sequence that is at least about 80% identical to the sequence of SEQ ID NO:8, wherein the polypeptide binds to LDL.

44. The nucleic acid of claim 43, wherein the amino acid sequence is at least about 90% identical to the sequence of SEQ ID NO:8.

45. The nucleic acid of claim 43, wherein the amino acid sequence is at least about 95% identical to the sequence of SEQ ID NO:8.

46. An isolated nucleic acid comprising a nucleotide sequence that encodes a polypeptide comprising the sequence of SEQ ID NO:8.

47. An isolated nucleic acid comprising a nucleotide sequence that encodes a polypeptide comprising an amino acid sequence that is at least about 80% identical to the sequence of SEQ ID NO:44, wherein the polypeptide binds to LDL.

48. The nucleic acid of claim 47, wherein the amino acid sequence is at least about 90% identical to the sequence of SEQ ID NO:44.

49. The nucleic acid of claim 47, wherein the amino acid sequence is at least about 95% identical to the sequence of SEQ ID NO:44.

50. An isolated nucleic acid comprising a nucleotide sequence that encodes a polypeptide comprising the sequence of SEQ ID NO:44.

51. The nucleic acid of claim 50, wherein the polypeptide consists of the sequence of SEQ ID NO:44.

52. An isolated nucleic acid comprising a nucleotide sequence that encodes a polypeptide comprising an amino acid sequence, wherein the amino acid sequence binds to LDL and is at least about 80% identical to a portion of the sequence of SEQ ID NO:5 or SEQ ID NO:8 that binds to LDL.

53. The nucleic acid of claim 52, wherein the amino acid sequence is at least about 90% identical to a portion of the amino acid sequence of SEQ ID NO:5 or SEQ ID NO:8.

54. The nucleic acid of claim 52, wherein the amino acid sequence is at least about 95% identical to a portion of the amino acid sequence of SEQ ID NO:5 or SEQ ID NO:8.

55. An isolated nucleic acid comprising a nucleotide sequence that encodes a polypeptide comprising an amino acid sequence, wherein the amino acid sequence binds to LDL



and is at least about 80% identical to a portion of the sequence of SEQ ID NO:44 that binds to LDL.

56. The nucleic acid of claim 55, wherein the amino acid sequence is at least about 90% identical to a portion of the amino acid sequence of SEQ ID NO:44.

57. The nucleic acid of claim 55, wherein the amino acid sequence is at least about 95% identical to a portion of the amino acid sequence of SEQ ID NO:44.

58. An isolated nucleic acid comprising a nucleotide sequence that encodes a polypeptide comprising an amino acid sequence identical to a fragment of at least ten amino acid residues of SEQ ID NO:5.

59. The nucleic acid of claim 58, wherein the polypeptide binds to LDL.

60. The nucleic acid of claim 58, wherein the amino acid sequence is identical to a fragment of at least about 20 amino acid residues of SEQ ID NO:5.

61. The nucleic acid of claim 58, wherein the amino acid sequence is identical to a fragment of at least about 30 amino acid residues of SEQ ID NO:5.

62. The nucleic acid of claim 58, wherein the amino acid sequence comprises SEQ ID NO:29 or SEQ ID NO:41.

63. An isolated nucleic acid comprising a nucleotide sequence that encodes a polypeptide comprising an amino acid sequence identical to a fragment of at least ten amino acid residues of SEQ ID NO:8.

64. The nucleic acid of claim 63, wherein the polypeptide binds to LDL.

65. The nucleic acid of claim 63, wherein the amino acid sequence is identical to a fragment of at least about 20 amino acid residues of SEQ ID NO:8.

66. The nucleic acid of claim 63, wherein the amino acid sequence is identical to a fragment of at least about 30 amino acid residues of SEQ ID NO:8.

67. An isolated nucleic acid comprising a nucleotide sequence that encodes a polypeptide comprising an amino acid sequence identical to a fragment of at least ten amino acid residues of SEQ ID NO:44.

68. The nucleic acid of claim 67, wherein the polypeptide binds to LDL.

69. The nucleic acid of claim 67, wherein the amino acid sequence is identical to a fragment of at least about 20 amino acid residues of SEQ ID NO:44.

70. The nucleic acid of claim 67, wherein the amino acid sequence is identical to a fragment of at least about 30 amino acid residues of SEQ ID NO:44.

71. An isolated nucleic acid comprising a nucleotide sequence that encodes a polypeptide comprising an amino acid sequence, wherein the amino acid sequence binds to LDL and differs by one or more conservative amino acid substitutions from the sequence of SEQ ID NO:5 or SEQ ID NO:8.

72. An isolated nucleic acid comprising a nucleotide sequence that encodes a polypeptide comprising an amino acid sequence, wherein the amino acid sequence binds to LDL and differs by one or more conservative amino acid substitutions from the sequence of SEQ ID NO:44.

73. An isolated nucleic acid comprising a nucleotide sequence that encodes a polypeptide comprising an amino acid sequence, wherein the amino acid sequence binds to LDL

and differs by one or more conservative amino acid substitutions from the sequence of a fragment of at least ten amino acid residues of SEQ ID NO:5 or SEQ ID NO:8.

74. The nucleic acid of claim 73, wherein the amino acid sequence differs by one or more conservative amino acid substitutions from the sequence of a fragment of at least about 20 amino acid residues of SEQ ID NO:5 or SEQ ID NO:8.

75. The nucleic acid of claim 73, wherein the amino acid sequence differs by one or more conservative amino acid substitutions from the sequence of a fragment of at least about 30 amino acid residues of SEQ ID NO:5 or SEQ ID NO:8.

76. An isolated nucleic acid comprising a nucleotide sequence that encodes a polypeptide comprising an amino acid sequence, wherein the amino acid sequence binds to LDL and differs by one or more conservative amino acid substitutions from the sequence of a fragment of at least ten amino acid residues of SEQ ID NO:44.

77. The nucleic acid of claim 76, wherein the amino acid sequence differs by one or more conservative amino acid substitutions from the sequence of a fragment of at least about 20 amino acid residues of SEQ ID NO:44.

78. The nucleic acid of claim 76, wherein the amino acid sequence differs by one or more conservative amino acid substitutions from the sequence of a fragment of at least about 30 amino acid residues of SEQ ID NO:44.

79. An isolated nucleic acid comprising a nucleotide sequence that specifically hybridizes to the sequence of SEQ ID NO:14 or SEQ ID NO:17.

80. The nucleic acid of claim 79, wherein the nucleotide sequence encodes a polypeptide that binds to LDL.

81. The nucleic acid of claim 79, wherein the nucleotide sequence is at least about 80% identical to the sequence of SEQ ID NO:14 or SEQ ID NO:17.

82. The nucleic acid of claim 79, wherein the nucleotide sequence is at least about 95% identical to the sequence of SEQ ID NO:14 or SEQ ID NO:17.

83. The nucleic acid of claim 79, wherein the nucleotide sequence comprises the sequence of SEQ ID NO:14 or SEQ ID NO:17.

84. An isolated nucleic acid comprising a nucleotide sequence that specifically hybridizes to the sequence of SEQ ID NO:46.

85. The nucleic acid of claim 84, wherein the nucleotide sequence encodes a polypeptide that binds to LDL.

86. The nucleic acid of claim 84, wherein the nucleotide sequence is at least about 80% identical to the sequence of SEQ ID NO:46.

87. The nucleic acid of claim 84, wherein the nucleotide sequence is at least about 95% identical to the sequence of SEQ ID NO:46.

88. The nucleic acid of claim 84, wherein the nucleotide sequence comprises the sequence of SEQ ID NO:46.

89. An isolated nucleic acid comprising the nucleotide sequence of SEQ ID NO:40 or SEQ ID NO:42.

90. A recombinant vector comprising the nucleic acid of claim 38.

91. A recombinant vector comprising the nucleic acid of claim 43.

10/27/2016 11:23:00 AM

93. A cell comprising the recombinant vector of claim 91.

94. A method of producing a polypeptide, the method comprising culturing the cell of claim 92 under conditions that permit expression of the polypeptide.

95. A method of producing a polypeptide, the method comprising culturing the cell of claim 93 under conditions that permit expression of the polypeptide.--

	1970	1971	1972	1973	1974	1975	1976	1977	1978	1979	1980	1981	1982	1983	1984	1985	1986	1987	1988	1989	1990	1991	1992	1993	1994	1995	1996	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026	2027	2028	2029	2030	2031	2032	2033	2034	2035	2036	2037	2038	2039	2040	2041	2042	2043	2044	2045	2046	2047	2048	2049	2050	2051	2052	2053	2054	2055	2056	2057	2058	2059	2060	2061	2062	2063	2064	2065	2066	2067	2068	2069	2070	2071	2072	2073	2074	2075	2076	2077	2078	2079	2080	2081	2082	2083	2084	2085	2086	2087	2088	2089	2090	2091	2092	2093	2094	2095	2096	2097	2098	2099	2100	2101	2102	2103	2104	2105	2106	2107	2108	2109	2110	2111	2112	2113	2114	2115	2116	2117	2118	2119	2120	2121	2122	2123	2124	2125	2126	2127	2128	2129	2130	2131	2132	2133	2134	2135	2136	2137	2138	2139	2140	2141	2142	2143	2144	2145	2146	2147	2148	2149	2150	2151	2152	2153	2154	2155	2156	2157	2158	2159	2160	2161	2162	2163	2164	2165	2166	2167	2168	2169	2170	2171	2172	2173	2174	2175	2176	2177	2178	2179	2180	2181	2182	2183	2184	2185	2186	2187	2188	2189	2190	2191	2192	2193	2194	2195	2196	2197	2198	2199	2200	2201	2202	2203	2204	2205	2206	2207	2208	2209	2210	2211	2212	2213	2214	2215	2216	2217	2218	2219	2220	2221	2222	2223	2224	2225	2226	2227	2228	2229	2230	2231	2232	2233	2234	2235	2236	2237	2238	2239	2240	2241	2242	2243	2244	2245	2246	2247	2248	2249	2250	2251	2252	2253	2254	2255	2256	2257	2258	2259	2260	2261	2262	2263	2264	2265	2266	2267	2268	2269	2270	2271	2272	2273	2274	2275	2276	2277	2278	2279	2280	2281	2282	2283	2284	2285	2286	2287	2288	2289	2290	2291	2292	2293	2294	2295	2296	2297	2298	2299	2300	2301	2302	2303	2304	2305	2306	2307	2308	2309	2310	2311	2312	2313	2314	2315	2316	2317	2318	2319	2320	2321	2322	2323	2324	2325	2326	2327	2328	2329	2330	2331	2332	2333	2334	2335	2336	2337	2338	2339	2340	2341	2342	2343	2344	2345	2346	2347	2348	2349	2350	2351	2352	2353	2354	2355	2356	2357	2358	2359	2360	2361	2362	2363	2364	2365	2366	2367	2368	2369	2370	2371	2372	2373	2374	2375	2376	2377	2378	2379	2380	2381	2382	2383	2384	2385	2386	2387	2388	2389	2390	2391	2392	2393	2394	2395	2396	2397	2398	2399	2400	2401	2402	2403	2404	2405	2406	2407	2408	2409	2410	2411	2412	2413	2414	2415	2416	2417	2418	2419	2420	2421	2422	2
--	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	---

REMARKS

Claims 38-95 are pending in the application, claims 1-37 having been cancelled without prejudice, and claims 38-95 having been added by the above amendment. Support for new claims 38-95 can be found, e.g., in original claims 1-14 and in the specification at: page 2, lines 19-30; page 8, line 11, to page 11, line 12; page 17, line 7, to page 18, line 15; page 21, lines 2-18; page 27, line 1, to page 28, line 3; and page 32, line 22, to page 33, line 6. These amendments add no new matter.

The present application is a divisional of U.S. Patent Application No. 09/616,289, filed July 14, 2000. The claims of this divisional application are directed to LBP-3 nucleic acids, recombinant vectors, host cells, and methods of producing LBP-3 polypeptides. The claims of the parent application (Serial No. 09/616,289) are directed to LBP-2 polypeptides.

CONCLUSIONS

Attached is a marked-up version of the changes being made by the current amendment. Applicants ask that all claims be examined.

Enclosed is a check for the basic filing fee and claims fees. Please apply any other charges or credits to Deposit Account No. 06-1050, referencing Attorney Docket No. 10797-004004.

Respectfully submitted,

Date: December 17, 2001

Jack Brennan  
Jack Brennan  
Reg. No. 47,443

Fish & Richardson P.C.  
225 Franklin Street  
Boston, Massachusetts 02110-2804  
Telephone: (617) 542-5070  
Facsimile: (617) 542-8906

**Version with Markings to Show Changes Made**

In the Specification:

The paragraph beginning at page 1, line 5, has been amended as follows:

This application is a divisional of U.S. Patent Application No. 09/616,289, filed July 14, 2000, which is a continuation-in-part of U.S. Patent Application No. [USSN] 09/517,849, filed March 2, 2000, which is [was] a continuation-in part of U.S. Patent Application No. [USSN] 08/979,608, filed November 26, 1997, which claimed priority from U.S. Provisional Application No. [USSN] 60/031,930, filed November 27, 1996, and U.S. Provisional Application No. [USSN] 60/048,547, filed June 3, 1997. These applications are incorporated herein by reference in their entirety.

The paragraph beginning at page 6, line 7, has been amended as follows:

Fig. 3 depicts the amino acid sequence of amino acids 319 to [350] 550 of rabbit LBP-2 (SEQ ID NO: 3).

The paragraph beginning at page 6, line 9, has been amended as follows:

Fig. 4 depicts the amino acid sequence of amino acids 299 to [350] 550 of rabbit LBP-2 (SEQ ID No: 4).

The paragraph beginning at page 6, line 28, has been amended as follows:

Fig. 10 depicts the cDNA sequence encoding rabbit LBP-1 (SEQ ID NO: 10) and the corresponding amino acid sequence (SEQ ID NO:1). Differences in amino acids between rabbit and human LBP-1 are depicted in bold type.

The paragraph beginning at page 6, line 31, has been amended as follows:

Fig. 11 depicts a cDNA sequence encoding a portion of rabbit LBP-2 (SEQ ID NO: 11) and the corresponding amino acid sequence (SEQ ID NO:2). Differences in amino acids between rabbit and human LBP-2 are depicted in bold type. Where the sequences depicted in Fig. 2A and

Fig. 11 differ, Fig. 2A represents the rabbit LBP-2 sequence.

The paragraph beginning at page 7, line 4, has been amended as follows:

Fig. 12 depicts a cDNA sequence of nucleotides 256 to 1617 (SEQ ID NO: 12) of SEQ ID NO: 11 of rabbit LBP-2 and the corresponding amino acid sequence (SEQ ID NO:3).

The paragraph beginning at page 7, line 6, has been amended as follows:

Fig. 13 depicts a cDNA sequence of nucleotides 196 to 1617 (SEQ ID NO: 13) of SEQ ID NO: 11 of rabbit LBP-2 and the corresponding amino acid sequence (SEQ ID NO:4).

The paragraph beginning at page 7, line 8, has been amended as follows:

Fig. 14 depicts the cDNA sequence encoding rabbit LBP-3 (SEQ ID NO: 14) and the corresponding amino acid sequence (SEQ ID NO:5). Differences in amino acids between rabbit and human LBP-3 are depicted in bold type.

The paragraph beginning at page 7, line 11, has been amended as follows:

Fig. 15 depicts the cDNA sequence encoding human LBP-1 (SEQ ID NO: 15) and the corresponding amino acid sequence (SEQ ID NO:6). Differences in amino acids between rabbit and human LBP-1 are depicted in bold type.

The paragraph beginning at page 7, line 14, has been amended as follows:

Fig. 16 depicts a cDNA sequence encoding a portion of human LBP-2 (SEQ ID NO: 16) and the corresponding amino acid sequence (SEQ ID NO:7). Differences in amino acids between rabbit and human LBP-2 are depicted in bold type.

The paragraph beginning at page 7, line 17, has been amended as follows:

Fig. 17 depicts a cDNA sequence encoding a portion of human LBP-3 (SEQ ID NO: 17) and the corresponding amino acid sequence (SEQ ID NO:8). Differences in amino acids between rabbit and human LBP-3 are depicted in bold type. Where the sequences depicted in Fig. 8A and Fig. 17 differ, Fig. 8A represents the human LBP-3 sequence.

100333-12701  
FOZTET-EEEEE



The paragraph beginning at page 7, line 21, has been amended as follows:

Fig. 18 depicts the cDNA sequence encoding BHF-1 (SEQ ID NO: 18) and  
corresponding amino acid sequence (SEQ IDNO:9).

The paragraph beginning at page 7, line 22, has been amended as follows:

Fig. 19 corresponds to the amino acid sequence of rabbit LBP-1 (top sequence; SEQ ID  
NO:1) in alignment with the amino acid sequence of human LBP-1 (bottom sequence; SEQ ID  
NO:6).

The paragraph beginning at page 7, line 24, has been amended as follows:

Fig. 20 corresponds to the amino acid sequence of a portion of the amino acid sequence  
of rabbit LBP-2 (top sequence; amino acid residues 331-550 of SEQ ID NO:47) in alignment  
with a portion of the amino acid sequence of human LBP-2 (bottom sequence; SEQ ID NO:7).

The paragraph beginning at page 7, line 27, has been amended as follows:

Fig. 21 corresponds to the amino acid sequence of rabbit LBP-3 (top sequence; SEQ ID  
NO:5) in alignment with the amino acid sequence of a portion of human LBP-3 (bottom  
sequence; SEQ ID NO:44).

The paragraph beginning at page 7, line 30, has been amended as follows:

Fig. 22 depicts the genomic sequence of human LBP-1 (SEQ ID NO:49) and  
corresponding amino acid sequence (SEQ ID NO:6).

The paragraph beginning at page 7, line 31, has been amended as follows:

Fig. 23 depicts the genomic sequence of human LBP-2 (SEQ ID NO:50) and  
corresponding amino acid sequence (SEQ ID NO:43).

The paragraph beginning at page 8, line 1, has been amended as follows:

Fig. 24 depicts the genomic sequence of human LBP-3 (SEQ ID NO:51) and

corresponding amino acid sequence (SEQ ID NO:44).

The paragraph beginning at page 8, line 11, has been amended as follows:

This invention provides for an isolated polynucleotide comprising a polynucleotide encoding the polypeptide having the amino acid sequence of rabbit LBP-1 as set forth in Fig. 1 (SEQ ID NO: 1); rabbit LBP-2 as set forth in Fig. 2A (SEQ ID NO: 47); a portion of rabbit LBP-2 as set forth in Fig. 2B (SEQ ID NO: 2); 319 to [350] 550 of rabbit LBP-2 as set forth in Fig. 3 (SEQ ID NO: 3); 299 to [350] 550 of rabbit LBP-2 as set forth in Fig. 4 (SEQ ID NO: 4); rabbit LBP-3 as set forth in Fig. 5 (SEQ ID NO: 5); human LBP-1 as set forth in Fig. 6 (SEQ ID NO: 6); human LBP-2 as set forth in Fig. 7A (SEQ ID NO: 43); 322 to 538 of human LBP-2 as set forth in Fig. 7B (SEQ ID NO: 7); human LBP-3 as set forth in Fig. 8A (SEQ ID NO: 44); 17-546 of human LBP-3 as set forth in Fig. 8B (SEQ ID NO: 8); 14 to 33 of human (SEQ ID NO:6) or rabbit (SEQ ID NO:1) LBP-1, called BHF-1, as set forth in Fig. 9 (SEQ ID NO: 9); a polynucleotide capable of hybridizing to and which is at least about 80% identical, more preferably at least about 90% identical, more preferably yet at least about 95% identical, and most preferably at least about 98% identical to any of the above polynucleotides, and wherein the encoded polypeptide is capable of binding to LDL; or a biologically active fragment of any of the above polynucleotides wherein the encoded polypeptide is capable of binding to LDL.

The paragraph beginning at page 11, line 26, has been amended as follows:

This invention also includes an isolated polypeptide comprising a polypeptide having amino acid residues 329-343 (SEQ ID NO: 19), 329-354 (SEQ ID NO: 20), 344-354 (SEQ ID NO: 21) or 529-538 (SEQ ID NO: 22) as set forth in Fig. 7A (SEQ ID NO: 47); amino acid residues 14-43 (SEQ ID NO: 23) or 38-43 (SEQ ID NO: 24) as set forth in Fig. 1 (SEQ ID NO: 1) and Fig. 6 (SEQ ID NO: 6); amino acid residues 338-353 (SEQ ID NO: 25), 338-365 (SEQ ID NO: 26), 354-365 (SEQ ID NO: 27) or 444-453 (SEQ ID NO: 28) as set forth in Fig. 2A (SEQ ID NO: 47); amino acid residues 96-110 (SEQ ID NO: 29) as set forth in Fig. 5 (SEQ ID NO: 5); and amino acid residues 69-75 (SEQ ID NO: 4i) as set forth in Fig. 8A (SEQ ID NO: [8] 44); or a polypeptide which is at least about 80% identical, more preferably at least about 90% identical, more preferably yet at least about 95% identical, and most preferably at least about 98% identical

to the above polypeptides, and wherein said polypeptide is capable of binding to LDL; or a biologically active fragment of any of the above polypeptides wherein the fragment is capable of binding to LDL.

The paragraph beginning at page 34, line 3, has been amended as follows:

Thus, a diagnostic embodiment of the invention is the adaptation of, e.g., a peptide complementary to one of the LBPs, by radiolabeling it and using it as an injectable imaging agent for detection of occult atherosclerosis. The peptide is selected from those known to bind to LBPs, e.g., RRRRRRR (SEQ ID NO:52) or KKLKLXX (SEQ ID NO:53), or any other polycationic peptide which binds to the highly electronegative domains of the LBPs. For extracorporeal detection with a gamma scintillation (Anger) camera, technetium-binding ligands, e.g., CGC, GGCGC, or GGCGCF, can be incorporated into the peptides at the N-terminus or C-terminus for <sup>99m</sup>Tc labeling. For external imaging by magnetic resonance imaging (MRI), e.g., the gadolinium-binding chelator, diethylene triamine penta-acetic acid (DTPA), is covalently bound to the N- or C-terminus of the peptides. In yet other embodiments, the LBP-binding peptides are covalently bound, e.g., to magnetic ion oxide particles by standard methods known to those skilled in the art, e.g., conjugating the peptides with activated polystyrene resin beads containing magnetic ion oxide.

In the Claims:

Claims 1-37 have been cancelled without prejudice.